Oncolytics Biotech Inc. (ONCY)
Pharmaceutical Preparations · market cap $88M · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
- 2026-12-12Conferenceimp 4/10
- 2027-07-30 (est.)Phase 2 · Pelareorepimp 7/10
- 2027-08-30 (est.)Phase 2 · Pelareorepimp 7/10
| Asset | Phase | Indication |
|---|---|---|
| Pelareorep | Phase 2 | Anal Cancer Metastatic |
| REOLYSIN | Phase 3 | Metastatic or Recurrent Squamous Cell Carcinoma of the Lung |
| REOLYSIN® | Phase 2 | Carcinoma, Non-small Cell Lung |
| Docetaxel, Reolysin and Prednisone | Phase 2 | Prostate Cancer |
| Pemetrexed and Reolysin (and safety run-in) | Phase 2 | Non Small Cell Lung Cancer |
| Trifluridine Tipiracil | Phase 2 | Anal Cancer Metastatic |
| Folfox plus Bevacizumab and reolysin | Phase 2 | Colorectal Cancer |
| mFOLFIRINOX Treatment Regimen | Phase 2 | Anal Cancer Metastatic |
| Docetaxel and Reolysin | Phase 2 | Non Small Cell Lung Cancer |
| Folfox plus Bevacizumab | Phase 2 | Colorectal Cancer |
Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for ONCY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
